Visanne (dienogest) / Mochida, Bayer - LARVOL DELTA

Sanleng Wan inhibits endometriosis progression by regulating sphingolipid metabolism via the S1P/S1PR1-Akt axis based on serum metabolomics and network pharmacology. (PubMed, J Ethnopharmacol) - "This study, utilizing serum metabolomics and network pharmacology, demonstrates the therapeutic effects of SLW in endometriosis model rats by modulating sphingolipid metabolism via the S1P/S1PR1-Akt axis, thereby enhancing understanding of its underlying mechanisms of action."

Journal • Endometriosis • Fibrosis • Gynecology • Immunology • Infertility • Metabolic Disorders • Musculoskeletal Pain • Pain • Sexual Disorders • Transplantation • Women's Health • S1PR1 • SPHK2 • TGFB1

GnRH analogues and dienogest for second line treatment of endometriosis-associated pain: a systematic review, meta-analysis, and network meta-analysis. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Oral GnRH antagonist has shown to be the most effective in improving dysmenorrhea and NMPP, as compared to the other drugs. However, dienogest was found more beneficial in the treatment of dyspareunia. These finding may serve clinical practitioners in electing medical therapy."

Journal • Retrospective data • Review • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

A Single-Center, Double-Arm, Randomized Controlled Clinical Study on the Treatment of Adenomyosis with Dienogest Combined with Magnetic Resonance-Guided Focused Ultrasound Ablation (ChiCTR) - P=N/A | N=76 | Not yet recruiting | Sponsor: Foshan Hospital of Traditional Chinese Medicine; Foshan Hospital of Traditional Chinese Medicine

New trial • Endometriosis • Women's Health

Do we need Placebo-Controlled Studies to Assess Medical Treatments of Pain Associated with Endometriosis? (WCE 2025) - "These included GnRh analogues, estrogen-progestin and progestin-only contraceptives, Dienogest and GnRh receptor antagonists. Data collection is nearing completion, full statistical studies are underway and will be presented at the conference. Conclusion All placebo-controlled studies have confirmed the efficacy of hormonally-induced amenorrhea in the treatment of pain associated with endometriosis, calling into question the ethical acceptability of this type of study in the evaluation of new drugs that induce amenorrhea."

Clinical • Endometriosis • Gynecology • Pain • Women's Health

Levonorgestrel Releasing Intrauterine System (LNG) versus Dienogest for the treatment of Adenomyosis (WCE 2025) - "LNG-IUS offers superior control of menstrual bleeding, more consistent pain relief, and a better overall safety profile. Dienogest may be considered as an alternative for women who prefer oral therapy ."

Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Treatment of Endometriosis – Focus on Improving Quality of Life (WCE 2025) - "The use of progestogens with affinity for receptors other than progesterone can lead to the development of side effects. In the presence of risks of endometriosis-associated complications, switching to dydrogesterone is recommended, since the presence of only a continuous regimen in dienogest limits its capabilities in terms of overcoming several undesirable effects. Group 2 patients were more likely to have endocrine and neurological diseases, which could possibly have influenced the occurrence of side effects and the need for early discontinuation of dienogest therapy."

HEOR • CNS Disorders • Depression • Endometriosis • Gynecology • Migraine • Pain • Psychiatry • Women's Health

Retroperitoneal Fibrosis: The Cause of Deep Endometriosis-Related Chronic Pelvic Pain (WCE 2025) - "Subsequent PV findings by another gynecologist reported CDS tenderness and resistance, favor pelvic endometriosis, which was treated with a 3-month GnRH agonist, followed by Dienogest...Hysterectomy alone without removal of retroperitoneal fibrosis is considered inadequate, resulting in persistent pain. Although extensive resection is effective, this mandates meticulous and expertise skills in retroperitoneal surgical dissection to achieve safe and optimal patient outcomes."

Endometriosis • Fibrosis • Gynecology • Immunology • Infertility • Inflammation • Musculoskeletal Pain • Pain • Sexual Disorders • Women's Health

Factors for Optimal Long-Term Control and Hormone-Sensitive Cancer Risks in Patients with Endometriosis: A Retrospective Cohort Study (WCE 2025) - "Medication types and dosages, including dienogest, danazol, combined oral contraceptives, levonorgestrel intrauterine device, and leuprolide were assessed. Conclusion In the Asian population, dienogest effectively reduced the need for definitive surgeries in patients with adenomyosis, but not for endometrioma, without increasing the risk of hormone- sensitive cancers and thromboembolic events. More evidence is needed from larger cohorts and long-term follow-up in populations of different ethnicities and cultures."

Retrospective data • Breast Cancer • CNS Disorders • Endometrial Cancer • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Oncology • Ovarian Cancer • Solid Tumor • Vascular Neurology • Women's Health

Dienogest Impact on DIE Lesions and Prognostic Treatment Selection Through Gene Expression and Histological Presentation (WCE 2025) - "The impact of NFKB and HSP90 inhibitors Triptolide and Luminespib on endometrial epithelial cells was validated in high content screening of organoids. Novel compounds for epithelial dominated endometriotic lesions were identified. Together this study provides a genuine pathway to stratify the current approach to endometriosis treatment."

Endometriosis • Fibrosis • Gynecology • Immunology • Women's Health • CDC37 • CXCL1 • CXCL12 • CXCR4 • PGR • SDC4

Medical treatment for adenomyosis: long term use of progestins. (PubMed, Gynecol Endocrinol) - "The treatment groups included dienogest (2 mg, n = 71), levonorgestrel-releasing intrauterine device (52 mg, n = 25), desogestrel (75 mcg, n = 20), and drospirenone (4 mg, n = 24)...Dienogest significantly reduced dysmenorrhea, dyspareunia, and HMB, with efficacy maintained over three years in most patients...Norethisterone acetate was used as a second-line treatment in cases of intolerance or inadequate response. Progestins are effective for the long-term management of adenomyosis symptoms. The flexibility in switching between different progestins or routes of administration may help in optimizing outcomes."

Journal • Endometriosis • Long-acting Reversible Contraceptives • Pain • Women's Health

Effects of dienogest treatment on endometrioma-related clinical symptoms and endometrioma size: retrospective cohort study. (PubMed, Front Med (Lausanne)) - "Similarly, the findings of T2 and each subsequent visit of the patients in the long-term group were compared with the initial findings and a significant reduction in endometrioma size and VAS scores was observed. Although the effectiveness of dienogest treatment for endometrioma seems to begin in the sixth month, its effectiveness maximizes in patients whose treatment duration is over 1 year."

Journal • Retrospective data • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis. (PubMed, Obstet Gynecol) - "This network meta-analysis indicates that leuprolide in combination with combined OCP, elagolix, vitamins C and E, and gestrinone may represent the most effective therapeutic options for alleviating endometriosis-associated pelvic pain, dysmenorrhea, dyspareunia, and nonmenstrual pelvic pain. These findings enhance our understanding of the relative efficacy of treatment strategies for pain associated with endometriosis. Future research should focus on conducting larger-scale and rigorously designed clinical trials within the target patient populations to further validate these results."

Journal • Retrospective data • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial. (PubMed, JMIR Res Protoc) - "This is the first trial to compare efficacy and safety between 1 mg/day and 2 mg/day of long-term dienogest use in patients with dysmenorrhea caused by endometriosis. Combining diagnostic imaging with patient questionnaires and blood tests allows the determination of efficacy against endometriosis itself."

Clinical protocol • Journal • Endometriosis • Gynecology • Pain • Women's Health

Dienogest vs. combined oral contraceptive: A systematic review and meta-analysis of efficacy and side effects to inform evidence-based guidelines. (PubMed, Acta Obstet Gynecol Scand) - "Dienogest is comparable to COC in terms of efficacy and tolerability. The therapeutic choice should be based on the patient's preference, clinical history, and experience."

Adverse events • Journal • Retrospective data • Review • Alopecia • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Role of Salivary MicroRNA as a Marker of Progesterone Resistance in Endometriosis: Preliminary Results from a Single-Institution Experience. (PubMed, Biomolecules) - "This aims to identify the differential miRNA expression profiles associated with therapeutic response to dienogest. Key miRNAs, including mir-3168, the mir-200a family, and mir-93-5p, emerged as potential biomarkers, showing significant differential expression linked to both endometriosis presence and treatment response. Further validation of these findings in larger cohorts could pave the way for miRNA-based diagnostic and prognostic tools, potentially reducing diagnostic delays and personalizing treatment approaches for endometriosis patients, also with new target therapies."

Biomarker • Journal • Endometriosis • Gynecology • Women's Health • MIR200A • MIR93

Comparative analysis of the efficacy of dienogest and LNG-IUS in the treatment of intrinsic and extrinsic subtypes of adenomyosis (PubMed, Zhonghua Fu Chan Ke Za Zhi) - "For patients with extrinsic adenomyosis, particularly those with prominent dysmenorrhea symptoms, DNG treatment offers greater benefits. However, for patients with intrinsic adenomyosis and those with significant menstrual disorders, a more cautious approach is required when selecting progestin therapy, along with enhanced monitoring and management."

Clinical • Journal • Retrospective data • Endometriosis • Gynecology • Oncology • Women's Health • MUC16

Hormonal Treatment of Endometriosis: A Narrative Review. (PubMed, Pharmaceuticals (Basel)) - "Progestins, particularly dienogest, demonstrate superior long-term efficacy with favorable side-effect profiles...Progestins are considered the most suitable long-term option. Despite promising results, evidence quality varies, and further studies are needed to establish long-term efficacy, patient-specific outcomes, and direct comparisons between agents."

Journal • Review • Endometriosis • Gynecology • Women's Health

Norethindrone acetate versus dienogest for pain relief in endometriosis related pain: A randomized controlled trial. (PubMed, Eur J Obstet Gynecol Reprod Biol) - P=N/A | "Both progestins effectively reduced pain scores, but NETA achieved a greater reduction in endometrioma size and had a lower dropout rate, potentially due to its higher dose. These findings suggest NETA 5 mg/day may be a better approach instead of dienogest for the endometriosis treatment."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Comparative analysis of the clinical efficacy of conservative treatment for adenomyosis using traditional Chinese medicine and Western medicine. (PubMed, J Health Popul Nutr) - "Dan'e Fukang Decoction is markedly effective in alleviating pain; Goserelin + Mirena exhibits significant efficacy in reducing bleeding."

Clinical • Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Add-on effect of curcumin to dienogest in patients with endometriosis: a randomized, double-blind, controlled trial. (PubMed, Phytomedicine) - "The combination of curcumin and dienogest significantly reduced pain and improved QOL and sexual function in women with endometriosis, suggesting curcumin as an effective adjunct therapy."

Clinical • Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

D-chiro-inositol effectively counteracts endometriosis in a mouse model. (PubMed, Mol Med) - "By modulating proliferation, EMT transition and aromatase activity, DCI emerges as a promising compound for endometriosis treatment."

Journal • Preclinical • Endometriosis • Gynecology • Infertility • Pain • Sexual Disorders • Transplantation • Women's Health • CD34 • CDH1 • CYP19A1 • PCNA • SIRT1

Reply to 'Critical appraisal of "Comparison of combined oral contraceptives and dienogest for endometriosis-associated pain"'. (PubMed, Eur J Obstet Gynecol Reprod Biol) - No abstract available

Journal • Endometriosis • Gynecology • Pain • Women's Health

Fertility preservation in women with endometriosis: A retrospective non-Inferiority study comparing Dienogest in the PPOS protocol to antagonist and agonist protocols. (PubMed, J Gynecol Obstet Hum Reprod) - "The PPOS protocol with Dienogest appears to be a promising alternative for FP compared to traditional protocols for patients with endometriosis, without adversely affecting the number of mature oocytes retrieved. Larger prospective studies are required to confirm these results."

Head-to-Head • Journal • Retrospective data • Endometriosis • Gynecology • Women's Health

ENDOmiRNA: Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy (clinicaltrials.gov) - P=N/A | N=90 | Recruiting | Sponsor: University of Udine | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: Jan 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Endometriosis • Gynecology • Women's Health

Efficacy and safety of hormone therapies for treating adenomyosis-associated pelvic pain: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, Front Endocrinol (Lausanne)) - "Dienogest seems to be the most effective HT for AAPP. However, although rare, it is also related to more adverse effects compared to other HTs. https://www.crd.york.ac.uk/prospero/, identifier CRD42024535472."

Clinical • Journal • Retrospective data • Review • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Musculoskeletal Pain • Pain • Women's Health